JAMA Editors' Summary JAMA at Kidney Week, JAMA Summit Report on Firearm Violence Reduction, AI for Drug Discovery, and more
8 snips
Nov 7, 2025 This week, groundbreaking research on rituximab shows increased relapse-free rates in adult nephrotic syndrome. Dialysis strategies in acute kidney injury are contrasted, revealing noteworthy recovery impacts. SGLT2 inhibitors prove beneficial for chronic kidney disease, while cystatin C levels unveil crucial mortality links. A viewpoint on patient participation in transplant selection brings diverse perspectives to light. The discussion also addresses actionable steps from the JAMA Summit to reduce firearm violence, alongside AI innovations in drug discovery.
AI Snips
Chapters
Transcript
Episode notes
Rituximab Reduces Nephrotic Relapses
- Rituximab markedly increased relapse-free rates in adults with frequently relapsing or steroid-dependent nephrotic syndrome at 49 weeks.
- The trial reported 87.4% relapse-free with rituximab versus 38% with placebo, suggesting clinical benefit despite lack of FDA approval for this indication in adults.
Conservative Dialysis May Boost AKI Recovery
- A conservative dialysis strategy for AKI may speed and increase kidney recovery compared with scheduled thrice-weekly dialysis.
- The Liberate-D trial suggests clinicians should reassess routine dialysis timing and ask why they start scheduled dialysis.
SGLT2 Inhibitors Work Across CKD Subgroups
- Meta-analyses show SGLT2 inhibitors reduce kidney outcomes, hospitalizations, and mortality regardless of diabetes status or albuminuria.
- Benefits on CKD progression held across baseline eGFR and urine albumin-to-creatinine ratios, supporting broad use.